Prevalence, Metabolic Profile, and Associated Risk Factors of Non-alcoholic Fatty Liver Disease in an Adult Population of India.

community obesity liver cirrhosis metabolic diseases nonalcoholic fatty liver disease (nafld) type 2 diabets mellitus

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Jan 2023
Historique:
accepted: 19 01 2023
entrez: 23 2 2023
pubmed: 24 2 2023
medline: 24 2 2023
Statut: epublish

Résumé

Introduction Non-alcoholic fatty liver disease (NAFLD) is the main cause of chronic liver disease worldwide. NAFLD refers to a group of diseases that includes simple steatosis, nonalcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma. Unfortunately, there aren't many studies on NAFLD conducted in India. The majority of research involved specific populations, such as diabetics, pregnant women with gestational diabetes, and obese or non-obese people. When the current study was being planned, there were few population-based studies available. In almost all of the research, ultrasound was employed to identify NAFLD, and the whole spectrum of NAFLD was not assessed. The full spectrum of NAFLD in India must have been considered, including all stages of steatosis as well as hepatic damage as shown by high alanine aminotransferase levels and fibrosis. The purpose of this study was to determine the prevalence, spectrum, and metabolic determinants of NAFLD as assessed by FibroScan® (FibroScan® expert 630 machine; Echosens, Paris, France) in adults of Central India. Methods This cross-sectional study was conducted among 236 adults aged 18 years and above in three localities of Bhopal, India from March 2022 to October 2022. The study included males and females who provided informed consent and fulfilled inclusion criteria. One research assistant and one staff nurse solicited people to participate in the FibroScan® test during the community screening and shared information about the programme. All participants were subjected to the FibroScan® test. Results A total of 322 healthy adults were approached for possible inclusion in the study. Data from 236 subjects were available for analysis after meeting the inclusion and exclusion criteria. According to this study, 43.6% of the study population had NAFLD as detected by FibroScan®. Out of the total, 12.7% of subjects had steatosis grade 1 (S1), 12.3% of subjects had steatosis grade 2 (S2), and 18.6% of subjects had steatosis grade 3 (S3). High body weight, high waist circumference, high waist-to-hip ratio, high fasting sugar, high serum glutamate pyruvate transaminase (SGPT), high triglyceride levels and high very low-density lipoprotein (VLDL) levels were significantly associated with NAFLD. Conclusion In conclusion, 43.6% of the adult population of Bhopal, India is suffering from NAFLD. NAFLD is a severe burden in the Indian community despite being historically associated with the western world. Obesity, diabetes and dyslipidemia are significantly associated with NAFLD.

Identifiants

pubmed: 36820120
doi: 10.7759/cureus.33977
pmc: PMC9938792
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e33977

Informations de copyright

Copyright © 2023, Singhai et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Eur Heart J. 2012 May;33(10):1190-200
pubmed: 22408036
J Hepatol. 2019 Mar;70(3):531-544
pubmed: 30414863
Metabolism. 2016 Aug;65(8):1136-50
pubmed: 26477269
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Hepatology. 2019 Jun;69(6):2672-2682
pubmed: 30179269
J Hepatol. 2017 Oct;67(4):862-873
pubmed: 28642059
Ann Hepatol. 2007 Jul-Sep;6(3):161-3
pubmed: 17786142
Indian J Med Res. 2009 Mar;129(3):285-92
pubmed: 19491421
Lancet Gastroenterol Hepatol. 2019 May;4(5):389-398
pubmed: 30902670
JGH Open. 2018 Dec 30;3(2):117-125
pubmed: 31061886
Can J Gastroenterol Hepatol. 2019 Oct 15;2019:6028952
pubmed: 31737583
Hepatology. 2010 May;51(5):1593-602
pubmed: 20222092
Hepatology. 2018 Jan;67(1):123-133
pubmed: 28802062
Indian J Gastroenterol. 2020 Feb;39(1):1-8
pubmed: 32152903
Diabetes Res Clin Pract. 2009 Apr;84(1):84-91
pubmed: 19168251
Liver Int. 2022 Aug;42(9):1955-1968
pubmed: 34459096
J Hepatol. 2015 Apr;62(1 Suppl):S47-64
pubmed: 25920090
J Assoc Physicians India. 2020 Aug;68(8):51-54
pubmed: 32738842
Nat Rev Gastroenterol Hepatol. 2013 Jun;10(6):330-44
pubmed: 23507799
J Hepatol. 2018 Oct;69(4):896-904
pubmed: 29886156
Am J Gastroenterol. 2018 Nov;113(11):1649-1659
pubmed: 29880964
Circulation. 2005 Oct 25;112(17):2735-52
pubmed: 16157765
N Engl J Med. 2010 Sep 30;363(14):1341-50
pubmed: 20879883
J Assoc Physicians India. 2011 Jun;59:351-4
pubmed: 21751587
BMJ Open. 2019 May 5;9(5):e027244
pubmed: 31061050

Auteurs

Abhishek Singhai (A)

General Medicine, All India Institute of Medical Sciences, Bhopal, Bhopal, IND.

Vikas Yadav (V)

Environmental Health and Epidemiology, Indian Council of Medical Research-National Institute for Research in Environmental Health, Bhopal, IND.

Rajnish Joshi (R)

Internal Medicine, All India Institute of Medical Sciences, Bhopal, Bhopal, IND.

Rajesh Malik (R)

Radiodiagnosis, All India Institute of Medical Sciences, Bhopal, IND.

Savitha B T (SB)

General Medicine, All India Institute of Medical Sciences, Bhopal, IND.

Sarita Kamle (S)

General Medicine, All India Institute of Medical Sciences, Bhopal, IND.

Classifications MeSH